Výsledky vyhledávání - "Bonnie Bielefeld"

The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5years and older treated with intravenous idursulfase

Autor: Bonnie Bielefeld, Ann J. Barbier, D.A. Amato, David A.H. Whiteman, M. Natarajan, Arian Pano

Publikováno v: Molecular Genetics and Metabolism. 110:303-310

In the pivotal phase II/III trial of idursulfase administered intravenously to treat mucopolysaccharidosis II, approximately half of the patients developed antibodies to idursulfase. This post-hoc analysis of data from the phase II/III trial and exte

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1f6a6d544c75df12248f1a5aaf23968
https://doi.org/10.1016/j.ymgme.2013.08.002

Zobrazit plný text záznamu

Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)

Autor: Ann J. Barbier, David A Amato, Bonnie Bielefeld, Arian Pano, David A.H. Whiteman

Publikováno v: Orphanet Journal of Rare Diseases

Background Twenty-eight treatment-naïve mucopolysaccharidosis II patients (16 months–7.5 years) received 0.5 mg/kg idursulfase weekly for one year in NCT00607386. Serum anti-idursulfase immunoglobulin G antibodies (Abs) were seen in 68% of patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02e10b3701f7012505050afdf718941f
https://doi.org/10.1186/s13023-015-0265-2

Zobrazit plný text záznamu

Limited clinical impact of anti-idursulfase antibodies developed during long-term idursulfase enzyme replacement therapy (ERT) in mucopolysaccharidosis II (MPS II, Hunter syndrome) patients aged 5-35 years

Autor: Christian J. Hendriksz, Ann J. Barbier, Yune Kunes, Ashok Vellodi, Bonnie Bielefeld, Roberto Giugliani, Suresh Vijayaraghavan, Paul Harmatz, Kenneth Sciarappa, Arian Pano, Nancy J. Mendelsohn

Publikováno v: Molecular Genetics and Metabolism. 111:S53

38% by 240 weeks (n= 5). Forced expiratory volume (FEV1) increased approximately 11% at 96 weeks (n = 33) and was maintained at 240 weeks (n= 5) (3). After 7 years, FVC improved by 47% (n= 5) and FEV1 by 34% (n= 6), showing continued upward trajector

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d72b22590495820ef0ce15009fd6c75
https://doi.org/10.1016/j.ymgme.2013.12.113

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání